Last reviewed · How we verify

NCT02622451

Differential Sensitivity Markers in Youth Drug Abuse Prevention

Completed NA Last updated 21 September 2020
What this trial tests

NA trial testing Teen Intervene in Adolescent Substance Use in 32 participants. Completed in 8 March 2020.

Timeline
1 December 2015
Primary endpoint
8 March 2020
8 March 2020

Quick facts

Lead sponsorUniversity of Minnesota
PhaseNA
StatusCompleted
Study typeINTERVENTIONAL
Allocationrandomized
Designparallel
Maskingnone
Primary purposeprevention
Enrollment32
Start date1 December 2015
Primary completion8 March 2020
Estimated completion8 March 2020
Sites1 location across United States

Drugs / interventions tested

Conditions studied

Sponsor

University of Minnesota

Who can join

Adults 12 to 17, any sex, with Adolescent Substance Use. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

This pilot study conducts feasibility and exploratory intervention outcome research that will lead to the development of a personalized intervention framework that seeks to preempt the progression from early drug use to more chronic abuse and dependency. The study will explore moderators representing two frameworks, risk severity and differential sensitivity. Moderators will be explored in their ability to influence the differential efficacy of two adolescent drug abuse interventions.

Publications & conference data

No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.

Verify or expand the search:

Other recruiting trials for Adolescent Substance Use

Currently open trials in the same condition.

Other University of Minnesota trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT02622451.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing